Drugs / BL-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05818306 | Feb → May 2023 | — | Bloom Science | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-03-04 | Bloom Science | Results Bloom Science Reports Positive Data from Phase 1 Trial of BL-001 bloomscience.com ↗
The overall treatment effect of BL-001 on weight loss (all treated BL-001 (n=24) vs Placebo (n=8)) was statistically significant (p=0.0424; MMRM, mixed model repeated measures) over the 28-day treatment period. |
| 2023-08-17 | Bloom Science | Results Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS bloomscience.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05818306 ↗ |
| Modality | Other / unclassified | “Live biological product BL-001” NCT05818306 ↗ |
| Route | Oral | “Oral, daily administration of BL-001 Dose 1 or Placebo” NCT05818306 ↗ |